US Patent 10259870 Anti-ANGPTL8 antibodies and uses thereof
Patent 10259870 was granted and assigned to Regeneron Pharmaceuticals on April, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 8 May, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+431 characters)
Article
Patent abstract
The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human ANGPTL8 with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized in part by elevated blood triglyceride levels.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Andrew J. Murphy0
David R. Buckler0
Jesper Gromada0
Viktoria Gusarova0
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 26 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102598700
Date of Patent
April 16, 2019
0Patent Application Number
152283980
Date Filed
August 4, 2016
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 25 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10259870 Anti-ANGPTL8 antibodies and uses thereof
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10259870
Date of patent
April 16, 2019
Patent application number
15228398
Date Filed
August 4, 2016
Patent primary examiner
Find more entities like US Patent 10259870 Anti-ANGPTL8 antibodies and uses thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
